Snipr’s Crispr-Cas bacteriophage kills resistant E. coli
Snipr Biome ApS has published initial clinical data showing its Crispr-Cas modified bacteriophage product selectively kills Escherichia coli – including strains that are resistant to antibiotics – ...
Learn how to Weed it G'out at this year's NKF Cleveland Kidney Walk
The medical director at Horizon Therapeutics and the executive director at the National Kidney Foundation (NKF) of Ohio ...
Advances in nanotechnology application in biosafety materials A crucial response to COVID-19 pandemic
Insight into the concept of biosafety materials for combating COVID-19 is presented. The advances in nanotechnology to develop diagnostics and therapeutics are highlighted. The increasing demand for ...
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
Meanwhile, key regulatory and pipeline updates from bigwigs like GSK GSK and Biogen BIIB were in the spotlight too during the week ... which is being developed in collaboration with Denali ...
Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 ...
May 31, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR ...
CRSP Jun 2023 64.000 put
Here, I discuss the central investing thesis for its fellow CRISPR/Cas9 gene-editing specialist, Intellia Therapeutics (NASDAQ: NTLA). CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What ...
CRISPR Therapeutics AG [CRSP] stock for 1,621,894 USD was sold by Kulkarni Samarth
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. CRISPR Therapeutics AG shares valued at $1,621,894 were sold by Kulkarni Samarth on May ...
Can This Gene-Editing Stock Deliver 10X Returns?
Gene-editing stocks have sunk under the weight of rising interest rates and high inflation. These macroeconomic headwinds, ...
Why Is CRISPR Therapeutics AG (CRSP) Up 1.8% Since Last Earnings Report?
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Beam Suntory releases Ardray blended Scotch whisky
The new release is inspired by Japanese blending traditions while aiming to "celebrate the excellence of blended Scotch ...
Beam heads home for superintendent job
Suzanne Stewart Staff Writer Last week, Pocahontas County Schools Superintendent Terrence Beam announced his resignation, effective June 30. Although he was a year away from retiring from the position ...
Sonos Beam soundbar just got an unprecedented price cut
The Sonos Beam is a great soundbar in the under $500 category, and it's even cheaper now thanks to this Best Buy deal.
BEAM - Beam Therapeutics Inc.
Beam Therapeutics (NASDAQ: BEAM) is exactly the kind of innovative biotech business that maverick growth stock investor Cathie Wood craves. Most recently, between April 27 and May 8, Wood bought ...
Innoviz Technologies Q1 2023 Earnings Preview
Innoviz Technologies (NASDAQ:INVZ) is scheduled to announce Q1 earnings results on Wednesday, May 17th, before market open. The consensus EPS Estimate is -$0.22 (+4.3% Y/Y) and the consensus ...
Building A Biotech Alliance Of Democracies
By Jafer Ahmad and Abigail Kukura WASHINGTON, DC - Like electricity and artificial intelligence, biotechnology is poised to ...
JMP Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price ...
SABS - SAB Biotherapeutics, Inc.
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176SIOUX ...
Sensei Biotherapeutics GAAP EPS of -$0.33 beats by $0.02
Sensei Biotherapeutics press release (NASDAQ:SNSE): Q1 GAAP EPS of -$0.33 beats by $0.02. Cash, cash equivalents and marketable securities were $95.5 million as of March 31, 2023, as compared to $ ...
Recap: Aeglea BioTherapeutics Q1 Earnings
Aeglea BioTherapeutics (NASDAQ:AGLE) reported its Q1 earnings results on Thursday, May 11, 2023 at 07:01 AM. Here's what investors need to know about the announcement. Aeglea BioTherapeutics ...
Poseida Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Looking ahead, revenue is expected to decline by 24% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 19%. Performance of the American ...